US Patent

US10238651 — Aripiprazole formulations having increased injection speeds

Method of Use · Assigned to Alkermes Pharma Ireland Ltd · Expires 2035-03-19 · 9y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects pharmaceutical compositions for the rapid intramuscular delivery of antipsychotic drugs.

USPTO Abstract

The present invention relates to pharmaceutical compositions comprising a compound of Formula (I) that are useful for the intramuscular delivery of antipsychotic drugs using rapid injection rates.

Drugs covered by this patent

Aristada (ARIPIPRAZOLE LAUROXIL) · Alkermes Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2402`	—	Aristada
`U-2402`	—	Aristada
`U-2402`	—	Aristada
`U-2402`	—	Aristada

Patent Metadata

Patent number: US10238651
Jurisdiction: US
Classification: Method of Use
Expires: 2035-03-19
Drug substance claim: No
Drug product claim: No
Assignee: Alkermes Pharma Ireland Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.